MedTrace Logo

Effects of Dexmedetomidine Used in Continuous Thoracic Paravertebral Blocks

NCT02619513 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2015-12-02

No results posted yet for this study

Summary

The purpose of this study is to explore the effectiveness of dexmedetomidine as an adjunctive analgesic, used in ultrasound-guided continuous thoracic paravertebral blocks for Post-thoracotomy Pain Syndrome(PTPS).

Conditions

  • Post-thoracotomy Pain Syndrome

Interventions

DRUG

Dexmedetomidine

Group GTD received thoracic continuous paravertebral nerve block with dexmedetomidine (0.5μg/kg) added to ropivacaine before anesthesia induction, and used continuous thoracic paravertebral nerve block patient-controlled analgesia(with dexmedetomidine 100μg）.

DRUG

Ropivacaine

Group GE\\GT\\GTD respectively received continuous nerve blocks and postoperative analgesia combined with ropivacaine.

DEVICE

Mindray M7 series

Ultrasound real-time guidance have been used in continuous thoracic paravertebral blocks in group GT and group GTD.

Sponsors & Collaborators

  • Weifeng Tu

    lead OTHER

Principal Investigators

  • Jie Peng, PhD · Guangzhou General Hospital of Guangzhou Military Command

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
76 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02619513 on ClinicalTrials.gov